Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …

Retrospective studies have suggested that older adolescents and young adults (AYAs) with
acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric …

Adults with relapsed B cell acute lymphoblastic leukemia (B-ALL) have a dismal prognosis.
Only those patients able to achieve a second remission with no minimal residual disease …

We investigated and modeled the mesenchymal stromal cell (MSC) niche in adult acute
lymphoblastic leukemia (ALL). We used gene expression profiling, cytokine/chemokine …

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL)
results in high cure rates in pediatric patients but is suboptimal in the treatment of adult …

Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs
in children between 2 and 10 years of age. L-asparaginase is an integral component of …

Vincristine (VCR) is a mainstay of treatment of hematologic malignancies and solid tumors
due to its well-defined mechanism of action, demonstrated anticancer activity and its ability …

Background Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin,
calicheamicin, has shown single-agent activity in relapsed or refractory acute lymphoblastic …

Acute Lymphoblastic Leukemia | New England Journal of Medicine Skip to main content Access
provided by Charite - Universitaetsmedizin Berlin The New England Journal of Medicine …